Skip to main content

Table 3 Ongoing phase III studies in front-line advanced/metastatic RCC

From: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Study

Primary endpoint

Sample size

National clinical trial identifier

Start time/status

Nivolumab + ipilimumab vs. sunitinib

PFS, OS

1070 (1:1)

NCT02231749

Oct 2014/on-going/enrollment closed

Atezolizumab + bevacizumab vs. sunitinib

PFS, OS

900 (1:1)

NCT02420821

May 2015/on-going

Avelumab + axitinib vs. sunitinib

PFS,

583 (1:1)

NCT02684006

March 2016/on-going

Pembrolizumab + axitinib vs. sunitinib

PFS, OS

840 (1;1)

NCT02853331

Sept 2016

Pembrolizumab + lenvatinib or everolimus + lenvatinib vs. sunitinib

PFS

735 (1:1:1)

NCT02811861

Sept 2016